Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
30.00
+0.68 (2.32%)
At close: Oct 7, 2026, 4:00 PM EDT
30.01
0.00 (0.02%)
After-hours: Oct 7, 2026, 7:30 PM EDT
LKFT Revenue
Lakefront Biotherapeutics NV had revenue of 13.66M EUR in the quarter ending June 30, 2026, a decrease of -81.44%. This brings the company's revenue in the last twelve months to 1.03B, up 227.88% year-over-year. In the year 2025, Lakefront Biotherapeutics NV had annual revenue of 1.17B with 268.41% growth.
Revenue (ttm)
1.03B EUR
Revenue Growth
+227.88%
P/S Ratio
1.70
Revenue / Employee
5,264,133 EUR
Employees
196
Market Cap
1.93B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 849.32M | 268.41% |
| Dec 31, 2024 | 316.42M | 29.43M | 10.25% |
| Dec 31, 2023 | 287.00M | 9.62M | 3.47% |
| Dec 31, 2022 | 277.38M | -3.08M | -1.10% |
| Dec 31, 2021 | 280.46M | -249.81M | -47.11% |
| Dec 31, 2020 | 530.26M | -355.54M | -40.14% |
| Dec 31, 2019 | 885.80M | 578.13M | 187.91% |
| Dec 31, 2018 | 307.67M | 151.75M | 97.33% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | 91.03M | 150.27% |
| Dec 31, 2015 | 60.58M | -29.44M | -32.70% |
| Dec 31, 2014 | 90.02M | -6.55M | -6.78% |
| Dec 31, 2013 | 96.57M | 4.35M | 4.71% |
| Dec 31, 2012 | 92.23M | -23.06M | -20.01% |
| Dec 31, 2011 | 115.29M | -21.27M | -15.57% |
| Dec 31, 2010 | 136.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Novavax | 413.80M |
| Vir Biotechnology | 303.23M |
| Xencor | 104.97M |
| Agios Pharmaceuticals | 98.34M |
| Zymeworks | 37.13M |
LKFT News
- 1 day ago - Acquisition of Own Shares - GlobeNewsWire
- 8 days ago - Acquisition of Own Shares - GlobeNewsWire
- 14 days ago - Lakefront Biotherapeutics Shares Jump 7.36% as Former Galapagos NV Continues Its Ongoing Corporate Reinvention - International Business Times (Australia)
- 14 days ago - Lakefront upgraded to Outperform from Sector Perform at RBC Capital - TheFly
- 15 days ago - Acquisition of Own Shares - GlobeNewsWire
- 16 days ago - Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig - MarketBeat
- 22 days ago - Lakefront Biotherapeutics NV Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 22 days ago - Acquisition of Own Shares - GlobeNewsWire